1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
The Cooper's 1-Year ROIIC % for the quarter that ended in Oct. 2024 was 14.25%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for The Cooper's 1-Year ROIIC % or its related term are showing as below:
COO's 1-Year ROIIC % is ranked better than 62.62% of 832
companies
in the Medical Devices & Instruments industry
Industry Median: 1.98
vs COO: 14.25
The Cooper 1-Year ROIIC % Historical Data
The historical data trend for The Cooper's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of The Cooper's 1-Year ROIIC %
For the Medical Instruments & Supplies subindustry, The Cooper's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper's 1-Year ROIIC % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where The Cooper's 1-Year ROIIC % falls into.
The Cooper 1-Year ROIIC % Calculation
The Cooper's 1-Year ROIIC % for the quarter that ended in Oct. 2024 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( 475.43009 (Oct. 2024) - 379.83375 (Oct. 2023) )
/
( 11947.1 (Oct. 2024) - 11276.2 (Oct. 2023) )
=
95.59634
/
670.9
=
14.25%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
The Cooper (NAS:COO) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
The Cooper 1-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of The Cooper's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COO has been successfully added to your 